Risk factors for persistent enterococcal bacteraemia: a multicentre retrospective study.


Journal

Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459

Informations de publication

Date de publication:
06 2022
Historique:
received: 18 02 2022
revised: 05 05 2022
accepted: 06 05 2022
pubmed: 16 5 2022
medline: 22 6 2022
entrez: 15 5 2022
Statut: ppublish

Résumé

Conditions favouring persistent enterococcal bacteraemia (p-EB) have not been fully investigated yet. The aim of our study is to analyse risk factors for p-EB and its impact on mortality. International two-centre retrospective study of all hospitalised adults with enterococcal bacteraemia managed with follow-up blood cultures (BCs) during the period 2011-2019. Exclusion criteria were: (1) death within 72 hours from index BCs and (2) polymicrobial bacteraemia. Primary endpoint was p-EB, defined as further isolation of the same species of Enterococcus spp. from BCs after at least 72 hours of appropriate antibiotic therapy. Multivariable logistic regression model was performed to assess risk factors for p-EB. The impact of p-EB on 30-day mortality was assessed by Kaplan-Meier survival curve and Cox regression multivariable model. During the study period, 244 enterococcal bacteraemia were diagnosed. P-EB were 13.5% (33/244). At multivariable analysis, factors independently associated with p-EB were hematologic malignancy (OR 4.60 [95% CI 1.32-16.00], P = 0.01), infective endocarditis (OR 7.99 [95% CI 2.20-28.9], P = 0.002), and use of daptomycin as initial treatment (OR 4.50 [95% CI 1.29-15.61], P = 0.018). Mortality rate was higher in the p-EB group (32% vs. 18%). Kaplan-Meier survival curve showed that patients with p-EB were less likely to survive at 30 days from index BCs (log-rank P = 0.002). Using a Cox regression model, independent predictors of 30-day mortality were hematologic malignancy (HR 2.30 [95% CI 1.02-4.11], P = 0.043), p-EB (HR 1.93 [95% CI 0.92-4.04], P = 0.08), and septic shock (HR 5.92 [95% CI 2.17-16.30], P = 0.001). P-EB was diagnosed mainly in very fragile patients and in those receiving daptomycin as frontline therapy. P-EB may have an impact on mortality.

Identifiants

pubmed: 35569757
pii: S2213-7165(22)00107-2
doi: 10.1016/j.jgar.2022.05.003
pii:
doi:

Substances chimiques

Daptomycin NWQ5N31VKK

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

386-389

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None to declare.

Auteurs

Linda Bussini (L)

Infectious Disease Unit, IRCCS Policlinico di Sant'Orsola, Bologna, Italy.

Elena Rosselli Del Turco (E)

Infectious Disease Unit, IRCCS Policlinico di Sant'Orsola, Bologna, Italy.

Zeno Pasquini (Z)

Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.

Kristian Scolz (K)

Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.

Alberto Amedeo (A)

Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.

Giacomo Beci (G)

Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.

Maddalena Giglia (M)

Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.

Sara Tedeschi (S)

Infectious Disease Unit, IRCCS Policlinico di Sant'Orsola, Bologna, Italy; Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.

Renato Pascale (R)

Infectious Disease Unit, IRCCS Policlinico di Sant'Orsola, Bologna, Italy.

Simone Ambretti (S)

Operative Unit of Microbiology, IRCCS Policlinico di Sant'Orsola, Bologna, Italy.

Juan M Pericàs (JM)

Infectious Diseases Service, Hospital Clínic de Barcelona, Spain; Liver Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research, Barcelona, Spain.

Maddalena Giannella (M)

Infectious Disease Unit, IRCCS Policlinico di Sant'Orsola, Bologna, Italy; Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.

Sulamita Carvalho-Brugger (S)

Intensive Care Unit, University Hospital Arnau de Vilanova, Lleida, Spain.

Laura Gutiérrez (L)

Infectious Diseases Service, University Hospital Arnau de Vilanova-University Hospital Santa Maria, Lleida, Spain.

Pierluigi Viale (P)

Infectious Disease Unit, IRCCS Policlinico di Sant'Orsola, Bologna, Italy; Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.

Michele Bartoletti (M)

Infectious Disease Unit, IRCCS Policlinico di Sant'Orsola, Bologna, Italy; Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy. Electronic address: m.bartoletti@unibo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH